The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice.
Find us at BOOTH #707
Symposia
Transforming VL care: new evidence, oral treatment innovation and pathways to elimination
Date: Thursday, 19 November 2026
Time: 8:00-9:45
Location: Potomac A (Ballroom level)
Chair: Fabiana Alves, Parasitic NTDs Cluster Director, DNDi
Speakers:
- Jain Saurabh, World Health Organization, Switzerland
- Srinivasa Rao, Novartis, California, USA
- Shyam Sundar, Banaras Hindu University, India
- Eleni Ayele, Gondar University Hospital, Ethiopia
- Isra Cruz, Instituto de Salud Carlos III, Spain
- Gláucia Cota, Head of Visceral Leishmaniasis Clinical Programme, DNDi
Advancing clinical guidelines for Chagas disease worldwide: insights from endemic and
non-endemic regions
Date: Friday, 20 November 2026
Time: 9:00-10:45
Location: Potomac C (Ballroom level)
Chairs:
- Clara Crespillo Andújar, Ramón y Cajal Hospital Madrid, Spain
- Crystal Y Zheng, Tulane University School of Medicine, Louisiana, USA
Speakers:
- João Carlos Pinto Dias, Fundação Oswaldo Cruz, Brazil
- Jaime Altcheh, Hospital de Niños Dr. Ricardo Gutierrez, Argentina
- Eva Clark, Baylor College of Medicine, Houston, USA
- Pau Bosch, Unitat de Salut Internacional Vall d’Hebron-Drassanes, Spain
- Dr María Jesús Pinazo Delgado, Head of Chagas disease, DNDi
Scientific sessions
Kinetoplastida and other opportunistic and anaerobic protozoa: Diagnosis and new detection tools
Date: Thursday, 19 November 2026
Time: 11:15-13:00
Location: National Harbor 10/11 (National Harbor Level)
| Predicting relapse in visceral leishmaniasis: Novel insights from an individual patient data meta-analysis Presenter: James Wilson, IDDO, University of Oxford, UK |
Measures for control and elimination of neglected tropical diseases I
Date: Saturday, 21 November 2026
Time: 9:00-10:45
Location: Maryland A (Ballroom level)
| Defining visceral leishmaniasis transmission hotspots in Kenya to guide targeted elimination strategies Presenter: Paul Kibati, Amref Health Africa, Kenya |
Kinetoplastida and other opportunistic and anaerobic protozoa: Epidemiology
Date: Saturday, 21 November 2026
Time: 9:00-10:45
Location: Maryland A (Ballroom level)
| Time from symptom onset to treatment initiation in visceral leishmaniasis in Brazil, 2007-2023: A national registry-based study Presenter: Prabin Dahal, IDDO, University of Oxford, UK |
American committee on clinical tropical medicine and travelers’ health (ACCTMTH) Symposium II: Global access to drugs for neglected tropical diseases
Date: Saturday, 21 November 2026
Time: 11:15-13:00
Location: Potomac B (Ballroom level)
| Needs-based R&D and access for neglected patients Presenter: Craig Tipple, DNDi, Switzerland |
Measures for control and elimination of neglected tropical diseases II
Date: Saturday, 21 November 2026
Time: 11:15-13:00
Location: Maryland C (Ballroom level)
| Beyond the thorn: Knowledge gaps, persistent myths and healthcare system barriers affecting mycetoma care in Turkana County, Kenya Presenter: Alice Sinkeet, African Institute for Health & Development, Kenya Prevalence and geographic distribution of mycetoma in Ethiopia: Findings from a community-based crosssectional survey Presenter: Dereje Bedane Hunde, Bahir Dar University, Ethiopia |
Posters
Date: Saturday, 21 November 2026
Time: 13:00-14:45
Location: Prince George’s Exhibition Hall A (Atrium level) – Poster hall
| Community engagement in the acceptability of acoziborole, a new single dose, oral treatment for gambiense human African trypanosomiasis in the Northern and Southern Ubangi provinces of DRC |
| Access to fexinidazole, a new oral treatment against rhodesiense human African trypanosomiasis in Eastern and Southern Africa |
| Efficacy and Safety of LXE408, a Novel Oral Treatment Candidate for Visceral Leishmaniasis: Results from a Phase II Study in Ethiopia (NCT05957978) |
| Transforming treatment of VL: a proof-of-concept study of LXE408, a Novel Oral Treatment for Visceral Leishmaniasis, in India |
| Safety of acoziborole in seropositive but parasitologically unconfirmed gambiense Human African Trypanosomiasis: Results from a multicentre randomized double-blind placebo-controlled trial |
More information about the event
DNDi New Strategic Plan 2027-2031
Date: Thursday, 19 November 2026
Time: 18:45 – 20:45
Location: Potomac 6
Join DNDi at ASTMH 2026 for an interactive dinner session featuring our R&D experts as we unveil our new Strategic Plan.
We invite ASTMH attendees to join the Drugs for Neglected Diseases initiative (DNDi) on Thursday, November 19 from 5:00pm-7:00pm for an open dialogue on DNDi’s new strategic plan, and to help us build the roadmap for its implementation over the next five years.
DNDi’s scientific and R&D leadership across several areas in our portfolio – drug discovery, leishmaniasis, dengue, pandemic preparedness, Chagas, and fungal diseases – will be on hand to discuss our strategic plan and identify areas of collaboration. This informal interactive session will include roundtable discussions where participants can connect directly with DNDi experts, ask questions, and propose and exchange ideas on the future of neglected disease R&D.
Speakers:
- Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi
- Glaucia Cota, Head of Visceral Leishmaniasis Clinical Programme, DNDi
- Dr Charles Mowbray, Discovery Director, DNDi
- Dr Maria Jesus Pinazo, Head of Chagas disease, DNDi
- Dr Borna Nyaoke-Anoke, Head of Mycetoma Disease, DNDi
- Laurent Fraisse, Research & Development Director, DNDi
- Craig Tipple, Medical Director, DNDi
